NP-011

MEDICATION RECONCILIATION IN AN EMERGENCY DEPARTMENT – PROCESS ASSESSMENT FOR A MORE EFFICIENT SERVICE

M Dreetz Holt, A Teigen, M Hermann, R Kjome. *Stavanger University Hospital, Stavanger, Norway*

10.1136/ejhp-2020-eahpconf.469

Background and importance Medication reconciliation (MR) is the process of providing an exact and accurate list of all medications a patient is taking. This process is necessary to ensure that patients get the correct medications when admitted to hospital, thus preventing drug related problems. The pharmacists in the emergency department at Stavanger University Hospital use a method based on IMM-methodology (Integrated Medicines Management) when executing MR. This is time consuming, partly due to asking patients open questions and the lack of electronic resources available at the time IMM-methodology was developed.

Aim and objectives This thesis aims to make the pharmacist's method for MR at the emergency department more efficient, thus obtaining correct medicine lists as early as possible for more patients.

Materials and methods An observation study surveyed possible improvements in the established method for MR at Stavanger University Hospital. This subsequently led to implementing a revised method for MR through an intervention study, comparing the methods with efficiency (time usage/patient) and quality (proportion of patients with discrepancies and number of discrepancies per patient). The revised method was deemed not qualitatively inferior to the established method if the proportion of discrepancies had a maximum deviation of 10%.

Results In total two hundred patients (78 years $\pm$ 10, 58% women) were included in the control group and currently hundred patients (78 years $\pm$ 9, 50% women) in the intervention group. The time usage for completing a MR in the intervention group was reduced by 34% compared to the control group. There was no difference in the proportion of patients with discrepancies/number of discrepancies per patient (respectively 79%/1.9 in the control group and 80%/1.9 in the intervention group).

Conclusion and relevance Data from the first 100 patients in the intervention group shows that the revised method for performing MR makes the process more efficient without significantly deterioration of quality.

NP-012

COST EFFECTIVENESS ANALYSIS AND INDIRECT COMPARISON CAN SUPPORT THE PRICE' DEFINITION OF A DRUG? THE CASE OF ENCORAFENIB AND BINIMETINIB IN METASTATIC MELANOMA, THE PHARMACIST'S POINT OF VIEW

¹A Marinozzi, ¹AMP Mangano, ¹E Antonicelli, ¹A Caprodossi, ¹R Connestari, ¹M Lalli, ¹E Maradonna, ²R Berardi, ¹L Patregnani. ¹PF Farmaceutica – ARS – Regione Marche, Ancona, Italy; ²AOU Ospedali Riuniti di Ancona – Clinica Oncologica, Ancona, Italy

10.1136/ejhp-2020-eahpconf.470

Background and importance The hospital pharmacist (HP) plays a key role in accessing new drugs at both regional and hospital level.

Aim and objectives The aim of this study is to propose a cost-effective approach, from the perspective of the HP, comparing the case of Encorafenib and Binimetinib, (EB) two BRAF

metastatic melanoma treatments (soon to be commercialized), with similar competitor drugs.

Materials and methods We developed a probabilistic model and a survey to quantify the economic impact of the price of these two new drugs. A cost-effectiveness model (in terms of OS) was developed using Montecarlo's simulations comparing EB vs Dabrafenib-Trametenib (DT) vs Vemurafenib-Cobimetinib (VC): The comparison arm of the 3 drugs registration studies was the Vemurafenib as the results of the arms were similar (both PFS and OS). In order to estimate the potential cost of EB (currently in negotiation), a survey was conducted within a Regional University Hospital taking into account Clinicians, HPs and Economists point of view.

Results The survey showed that EB could cost up to 18% more than DT, due to the 7.5-months of life gained (MoLG) more than the best competitor. The price emerged from the survey was used to conduct the cost-effectiveness analysis in order to estimate an incremental relationship between the alternatives. From the 10,000 simulations carried out considering a threshold value of € 5,000/MoLG emerged that EB was cost effective in 80% vs. DT showing an incremental ratio of € 4,239/MoLG; Furthermore, it was found to be cost effective in 83% vs. VC showing an incremental ratio of € 3,129/MoLG.

Conclusion and relevance EB potential cost could be more than the alternatives, but with a negotiation price similar to the available alternatives, the NHS would benefit in terms of health (MoLG) without significant additional expense. Furthermore, when direct comparisons are not available, it is advisable to analyze possible strategies of indirect comparison such as the Network metaanalysis. The methodology used in the survey to investigate the HP's willingness to pay could be a support tool that could be used from AIFA representatives to assess the perception of added value in the analysis of new therapeutic treatments.

NP-013

THE NEOCHECK PROJECT: DEVELOPMENT OF A PRESCRIPTION-SCREENING TOOL SPECIFIC TO NEONATOLOGY

^{1,2}Thomas Rudolf von Rohr, ³Roberta de Luca, ^{1,2}Pascal Bonnabry, ³Riccardo Pfister, ^{1,3}Caroline Fonzo-Christe. ¹Geneva University Hospitals, Pharmacy, Geneva, Switzerland; ²School of pharmaceutical sciences, University of Geneva, University of Lausanne, Geneva, Switzerland; ³Geneva University Hospitals, Neonatology and Pediatric Intensive Care Unit, Geneva, Switzerland

10.1136/ejhp-2020-eahpconf.471

Background and importance Neonatal pharmacotherapy is challenging and often based on little evidence. Off label use of drugs is common practice and patients are at a high risk of medication errors and drug-related problems. Prescription-screening tools are used in geriatrics, internal medicine and pediatrics to optimize drug prescribing.

Aim and objectives Our aim was to develop a prescription-screening tool specific to neonatology.

Materials and methods Clinical guidelines on neonatal pharmacotherapy were identified by a literature review and synthesized into short statements. A 2-rounds Delphi consensus method was used to establish the content validity of Neocheck. The statements were submitted to a group of 23 experts in 10 Swiss neonatology centers. The level of agreement was evaluated on a 5-point Likert scale (1 being the highest level of agreement). Statements for which >65% of

experts gave the statement a rating of 1 or 2 were selected at round 1. This cut off was raised to >75% at round two.

Results A total of 1375 clinical guidelines were identified from the literature search. After synthesis, 158 statements were submitted to the group of 23 Swiss experts. The mean agreement rating was 1.62 (95% CI 1.55 to 1.70) during the 1st round of Delphi and 1.32 (95% CI 1.28 to 1.37) during the 2nd round. The final Neocheck tool is composed of 141 statements on 11 medical domains and 49 neonatal diseases. On average, 95% (95% CI 94%-96%) of experts either totally agreed or slightly agreed with the validated statements.

Conclusion and relevance A prescription-screening tool specific to neonatology was developed and validated by a group of 23 Swiss experts. The impact of Neocheck on the optimization of drug use in neonates and its potential interest as a teaching tool for young physicians and clinical pharmacists need to be evaluated in the future.

NP-014

MEDICINE BOXES FOR DISTRIBUTION OF PAID PHARMACEUTICALS TO OUTPATIENTS IN THE FUTURE

C Olesen*, MN Pedersen, KBU Anthonen, MS Wellner. *Hospital Pharmacy Central Denmark Region, Aarhus, Denmark*

10.1136/ejhp-harm-2020-eahpconf.472

What was done? The process for distribution of paid pharmaceuticals (PPs) to outpatients in Central Denmark Region (13053 km², 1.3 million inhabitants) is made uniform and more flexible for the patients. Going forward, the patients will pick up their PPs in medicine boxes.

Why was it done? In Denmark, some expensive medications are provided without cost to a selected group of patients (paid pharmaceuticals, PPs). Approximately 35000 patients are

receiving PPs from the hospitals in Central Denmark Region, 40% from the hospital pharmacy, the rest directly from hospital wards. Going forward, the hospital pharmacy will take over a larger percentage of these patients. The reasoning behind this decision is to free up time at the hospital wards, increase quality and patient safety and create a model that meets patient needs.

How was it done? During development of the new model for distribution, patients and hospital staff were asked to identify important factors when handling and picking up PPs. A task-force has assessed different models, and decided to test a medicine box. When picking up PPs from the medicine box, the patient will receive a personal code delivered by SMS. They will enter the code in the medicine box to unlock the box and pick up their PPs.

What has been achieved? The medicine box was evaluated by patients in a questionnaire (n=71). 87% checked 'very satisfied' or 'satisfied' when evaluating distribution of PPs by the medicine box, while only 64% chose either of these categories for distribution by the hospital wards. An impressive 94% checked 'very satisfied' or 'satisfied' for operation of the medicine box.

The medicine box seems to address patient needs in a sufficient manner and fulfill the chosen standards for a future distribution model for PPs.

What next? 90% of patients receiving PPs from the hospital are expected to use the medicine box as a means of distribution in the future. 15 medicine boxes are being installed at 11 different locations in Central Denmark Region.

In the trial period, only pharmaceuticals suitable for keeping at room temperature were used in the medicine box. When implemented full scale, medicine boxes with cooling are also being installed.